Answers are grounded in this paper and cite their sources.
Phase 2 single-arm trial reports safety and efficacy of fosmanogepix in Candida auris candidemia, highlighting a novel treatment for drug-resistant fungal infections.
Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris .
No takes yet. Share an insight, caveat, or question.
Vázquez et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: